Research Study Category: Diagnosis

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication:  Antineutrophil Cytoplasmic …

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Sponsor: River 3 Renal Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)

Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease Sponsor: Amicus Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)

Protocol Name: Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease Primary Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim)

Protocol Name: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis Sponsor: Boehringer Ingelheim Indication: FSGS Primary Investigator: Anupkumar Shetty, MD Location: Charlton Office, 2651 Bolton Boone Drive, DeSoto, TX 75115 DETAILS >

Ziltivekimab Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (Novo Nordisk)

Protocol Name: ZEUS – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation Sponsor: Novo Nordisk Indication: Dual Diagnosis of Chronic Kidney Disease & Cardiovascular Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, …

Ziltivekimab Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (Novo Nordisk) Read More »

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis)

Protocol Name: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease (PERIDOT) Sponsor: Sanofi-Aventis Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (Otsuka)

Protocol Name: Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN) Sponsor: Otsuka Indication: IgA Nephropathy Primary Investigator: Dr. Bernard Fischbach Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >